The Importance of Weight Change Experiences for Performance of Diabetes Self-Care: A Patient-Centered Approach to Evaluating Clinical Outcomes in Type 2 Diabetes

Diabetes Therapy

Volumn 6, Issue 4, 2015, Pages 611-625

  Traina, Shana B ^a   Slee, April ^b   Woo, Sangsoon ^b   Canovatchel, William ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b Axio Research   (United States)

Author keywords

Behavior; Patient reported outcomes; Self care; Type 2 diabetes; Weight

Indexed keywords

CANAGLIFLOZIN; GLIMEPIRIDE PLUS METFORMIN; HEMOGLOBIN A1C;

ADULT; ARTICLE; CONTROLLED STUDY; DIET THERAPY; FEMALE; FOLLOW UP; HEALTH BEHAVIOR; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PHYSICAL PERFORMANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SELF CARE; SELF CONCEPT; SEXUAL BEHAVIOR; TREATMENT RESPONSE; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84949235980     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-015-0145-8     Document Type: Article

References (37)

1. American Association of Diabetes Educators Position Statement. AADE7 self-care behaviors. Diabetes Educ. 2008;34:445–9.
2. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.
3. Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev. 1977;84:191–215.
4. Tripp-Reimer T, Choi E, Skemp Kelley L, Enslein JC. Cultural barriers to care: inverting the problem. Diabetes Spectrum. 2001;14:13–22.
5. Glasgow RE, Toobert DJ, Gillette CD. Psychosocial barriers to diabetes self-management and quality of life. Diabetes Spectrum. 2001;14:33–41.
6. Coonrod BA. Overcoming physical barriers to diabetes self-care: reframing disability as an opportunity for ingenuity. Diabetes Spectrum. 2001;14:28–32.
7. Nam S, Chesla C, Stotts NA, Kroon L, Janson SL. Barriers to diabetes management: patient and provider factors. Diabetes Res Clin Pract. 2011;93:1–9.
8. Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: 4-year results of the Look AHEAD trial. Arch Intern Med. 2010;170:1566–75.
9. Kavookjian J. Motivational interviewing. Science and practice of pharmacotherapy I and II—PSAP-VII, Book 8. Lenexa: American College of Clinical Pharmacy; 2011. p. 1–18.
10. Miller WR, Rollnick S. Motivational interviewing: preparing people for change. New York: Guilford Press; 2002.
11. Song D, Xu TZ, Sun QH. Effect of motivational interviewing on self-management in patients with type 2 diabetes mellitus: a meta-analysis. Int J Nurs Sci. 2014;1:291–7.
12. Prochaska J, Norcross J. Systems of psychotherapy—a transtheoretical analysis. New York: Wadsworth Pub Co; 2003.
13. Elder JP, Ayala GX, Harris S. Theories and intervention approaches to health-behavior change in primary care. Am J Prev Med. 1999;17:275–84.
14. Johnson SS, Paiva AL, Cummins CO, Johnson JL, Dyment SJ, Wright JA, et al. Transtheoretical model-based multiple behavior intervention for weight management: effectiveness on a population basis. Prev Med. 2008;46:238–46.
15. Ruggiero L. Helping people with diabetes change behavior: from theory to practice. Diabetes Spectrum. 2000;13:125–31.
16. Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Health Promot. 1997;12:38–48.
17. Jones H, Edwards L, Vallis TM, Ruggiero L, Rossi SR, Rossi JS, et al. Changes in diabetes self-care behaviors make a difference in glycemic control: the diabetes stages of change (DiSC) study. Diabetes Care. 2003;26:732–7.
18. Graffigna G, Barello S, Libreri C, Bosio CA. How to engage type-2 diabetic patients in their own health management: implications for clinical practice. BMC Public Health. 2014;14:648.
19. Blake CE, Hebert JR, Lee DC, Adams SA, Steck SE, Sui X, et al. Adults with greater weight satisfaction report more positive health behaviors and have better health status regardless of BMI. J Obes. 2013;2013:291371.
20. Traina S, Guthrie R, Slee A. The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes. Postgrad Med. 2014;126:7–15.
21. Gabler NB, Duan N, Liao D, Elmore JG, Ganiats TG, Kravitz RL. Dealing with heterogeneity of treatment effects: is the literature up to the challenge? Trials. 2009;10:43.
22. Cefalu WT, Leiter LA, Yoon K-H, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941–50.
23. Leiter LA, Yoon K-H, Arias P, Langslet G, Xie J, Balis D, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, Phase 3 study. Diabetes Care. 2015;38:355–64.
24. Kolotkin RL, Crosby RD, Kosloski KD, Williams GR. Development of a brief measure to assess quality of life in obesity. Obes Res. 2001;9:102–11.
25. Talbot F, Nouwen A, Gingras J, Gosselin M, Audet J. The assessment of diabetes-related cognitive and social factors: the Multidimensional Diabetes Questionnaire. J Behav Med. 1997;20:291–312.
26. Lane S, Levy AR, Mukherjee J, Sambrook J, Tildesley H. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin. 2014;30:1267–73.
27. Bolin JH, Edwards JM, Finch WH, Cassady JC. Applications of cluster analysis to the creating of perfectionism profiles: a comparison of two clustering approaches. Front Psychol. 2014;5:1–9.
28. Wilding JP, Charpentier G, Hollander P, Gonzalez-Galvez G, Mathieu C, Vercruysse F, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013;67:1267–82.
29. Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582–92.
30. Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care. 2013;36:2508–15.
31. Ajzen I. The theory of planned behavior. Organizational and Human Decision Processes. 1991;50:179–211.
32. ® Health Questionnaire: Administration Guide for Clinical Trial Investigators. 2008.
33. Polonsky WH. Emotional and quality-of-life aspects of diabetes management. Curr Diab Rep. 2002;2:153–9.
34. Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2010;14:1–248.
35. Feldstein AC, Nichols GA, Smith DH, Stevens VJ, Bachman K, Rosales AG, et al. Weight change in diabetes and glycemic and blood pressure control. Diabetes Care. 2008;31:1960–5.
36. Feldstein AC, Nichols GA, Smith DH, Rosales AG, Perrin N. Weight change and glycemic control after diagnosis of type 2 diabetes. J Gen Intern Med. 2008;23:1339–45.
37. Walraven I, Mast MR, Hoekstra T, Jansen AP, van der Heijden AA, Rauh SP, et al. Distinct HbA1c trajectories in a type 2 diabetes cohort. Acta Diabetol. 2015;52:267–75.